Research ExplorerPublicationsA comparative performance analysis of total prostate-specifi...

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Standard

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. / Auprich, Marco; Augustin, Herbert; Budäus, Lars; Kluth, Louis; Mannweiler, Sebastian; Shariat, Shahrokh F; Fisch, Margit; Graefen, Markus; Pummer, Karl; Chun, Felix.

In: BJU INT, Vol. 109, No. 11, 11, 2012, p. 1627-1635.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Auprich, M, Augustin, H, Budäus, L, Kluth, L, Mannweiler, S, Shariat, SF, Fisch, M, Graefen, M, Pummer, K & Chun, F 2012, 'A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.', BJU INT, vol. 109, no. 11, 11, pp. 1627-1635. <http://www.ncbi.nlm.nih.gov/pubmed/21939492?dopt=Citation>

APA

Auprich, M., Augustin, H., Budäus, L., Kluth, L., Mannweiler, S., Shariat, S. F., Fisch, M., Graefen, M., Pummer, K., & Chun, F. (2012). A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU INT, 109(11), 1627-1635. [11]. http://www.ncbi.nlm.nih.gov/pubmed/21939492?dopt=Citation

Vancouver

Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU INT. 2012;109(11):1627-1635. 11.

Bibtex

@article{b2edb2bbac38462bacd21b2db5fe698e,
title = "A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.",
abstract = "Study Type - Diagnosis (exploratory cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Risk factor assessment in the repeat biopsy setting is affected by a decreasing diagnostic accuracy of each single risk factor (e.g. DRE, tPSA, %fPSA, complexed PSA, PSA density or PSAV] with increasing number of prostate biopsy sessions. PCA3 shows impressive diagnostic performance in the initial and early repeat biopsy settings. In a head-to-head comparison we demonstrate the concept that the number of previous repeat biopsy session strongly influences performance characteristics of biopsy risk factors, including PCA3. While the novel diagnostic marker would have avoided a considerable number of unnecessary biopsies in the first repeat biopsy scenario, its effects dissipated at second and ? third repeat biopsies.",
author = "Marco Auprich and Herbert Augustin and Lars Bud{\"a}us and Louis Kluth and Sebastian Mannweiler and Shariat, {Shahrokh F} and Margit Fisch and Markus Graefen and Karl Pummer and Felix Chun",
year = "2012",
language = "English",
volume = "109",
pages = "1627--1635",
journal = "BJU INT",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "11",

}

RIS

TY - JOUR

T1 - A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

AU - Auprich, Marco

AU - Augustin, Herbert

AU - Budäus, Lars

AU - Kluth, Louis

AU - Mannweiler, Sebastian

AU - Shariat, Shahrokh F

AU - Fisch, Margit

AU - Graefen, Markus

AU - Pummer, Karl

AU - Chun, Felix

PY - 2012

Y1 - 2012

N2 - Study Type - Diagnosis (exploratory cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Risk factor assessment in the repeat biopsy setting is affected by a decreasing diagnostic accuracy of each single risk factor (e.g. DRE, tPSA, %fPSA, complexed PSA, PSA density or PSAV] with increasing number of prostate biopsy sessions. PCA3 shows impressive diagnostic performance in the initial and early repeat biopsy settings. In a head-to-head comparison we demonstrate the concept that the number of previous repeat biopsy session strongly influences performance characteristics of biopsy risk factors, including PCA3. While the novel diagnostic marker would have avoided a considerable number of unnecessary biopsies in the first repeat biopsy scenario, its effects dissipated at second and ? third repeat biopsies.

AB - Study Type - Diagnosis (exploratory cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Risk factor assessment in the repeat biopsy setting is affected by a decreasing diagnostic accuracy of each single risk factor (e.g. DRE, tPSA, %fPSA, complexed PSA, PSA density or PSAV] with increasing number of prostate biopsy sessions. PCA3 shows impressive diagnostic performance in the initial and early repeat biopsy settings. In a head-to-head comparison we demonstrate the concept that the number of previous repeat biopsy session strongly influences performance characteristics of biopsy risk factors, including PCA3. While the novel diagnostic marker would have avoided a considerable number of unnecessary biopsies in the first repeat biopsy scenario, its effects dissipated at second and ? third repeat biopsies.

M3 - SCORING: Journal article

VL - 109

SP - 1627

EP - 1635

JO - BJU INT

JF - BJU INT

SN - 1464-4096

IS - 11

M1 - 11

ER -